AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Antigenics initiates Phase I clinical trial of AG-707 therapeutic vaccine for genital herpes.
(From Chemical Business NewsBase - Press Release)
Antigenics Inc has initiated a multicentre Phase I clinical trial of AG-707, its next-generation therapeutic vaccine for genital herpes. The study will evaluate the safety of and immune response to AG-707 in patients with herpes simplex virus type 2 (HSV-2). AG-707 is designed to stimulate a potent T-cell response against the virus to control and reduce the severity of infection. AG-707 (recombinant heat shock protein 70 polyvalent peptide complex) is a heat shock protein (HSP)-based vaccine that is designed to activate the immune system to target HSV-2 infection in a broad population of patients. AG-707 consists of a …
-
- Immune response of chimpanzees after immunization with the inactivated whole...
-
Newspaper article from: AIDS Weekly
May 17, 1993
700+ words
-
- MF9 adjuvanted vaccine shows strong immune response in A/H1N1: Novartis.
-
News wire article from: Chemical Business Newsbase
September 21, 2009
700+ words
-
- Intercell AG announces first subject enrolled in a phase II trial for the...
-
News wire article from: Chemical Business Newsbase
May 28, 2009
700+ words
-
- The Michael J Fox Foundation funds AFFiRiS AG to develop Parkinson's vaccine.
-
News wire article from: Chemical Business Newsbase
December 16, 2010
700+ words
-
- 3M Drug Delivery Systems signs licensing agreement with Spirig Pharma AG.
-
News wire article from: Chemical Business Newsbase
December 16, 2010
700+ words
